Logo image
Prognostic staging system for recurrent, persistent, and second primary cancers of the oral cavity and oropharynx
Journal article   Peer reviewed

Prognostic staging system for recurrent, persistent, and second primary cancers of the oral cavity and oropharynx

Bevan Yueh, Alvan R. Feinstein, Edward M. Weaver, Clarence T. Sasaki and John Concato
Archives of otolaryngology--head & neck surgery, Vol.124(9), pp.975-981
09/01/1998
DOI: 10.1001/archotol.124.9.975
PMID: 9738805

View Online

Abstract

Objective: To develop a practical staging system for predicting mortality of patients with recurrent squamous cell tumors of the oral cavity and oropharyngeal mucosa. Design and setting: An inception cohort at an academic medical center. Patients: A total of 308 patients who had evidence of recurrent, persistent, or second primary tumors of the oral cavity and oropharynx between January 1, 1980, and December 31, 1991, of whom 162 (52.6%) met inclusion criteria. Main outcome measure: One-year mortality. Results: The median survival time was 10 months. In bivariate analysis, the TNM stage of the recurrent tumor, invasion of pharyngeal constrictors and the floor-of-mouth muscles, weight loss, local and systemic symptoms, and eating function had significant effects on mortality. Multivariable analysis (done by conjunctive consolidation and Cox regression) identified constrictor invasion, the TNM stage of the recurrence, and weight loss as having a substantial effect on mortality. A composite 4-stage system using these 3 variables demarcated 1-year survival rates of 88.2% (30/34), 71.9% (23/32), 32.6% (16/49), and 4.2% (2/47). Conclusions: The TNM status of recurrent tumors predicts mortality, but constrictor muscle invasion and weight loss also have major prognostic importance. The consolidation of these variables into a composite staging system successfully stratifies patients with widely divergent mortality rates. Improved staging of recurrent head and neck tumors can lead to more effective decisions about the comparisons and merits of additional treatment.

Details

Metrics

Logo image